In order to accelerate innovation, local pharmaceutical companies still need to strengthen these aspects

In recent years, with the continuous deepening of medical reform and the continuous implementation of a series of policies to support the development of pharmaceutical innovation, the development of innovative drugs in China has begun to accelerate, and a series of results have gradually emerged
.
According to statistics, in November 2021, CDE has undertaken a total of 1018 new drug registration applications based on the acceptance number; among them, 726 are chemical medicines, 122 are Chinese medicines, and 170 are biological products
.
Local pharmaceutical companies have a lot of tricks to accelerate innovation (Image source: Pharma.
com) In order to accelerate innovation, local pharmaceutical companies have a lot of tricks.
In fact, it can be seen from the above that the innovation capabilities of domestic pharmaceutical companies are constantly improving
.
It is worth mentioning that many pharmaceutical companies in China are actually increasing their investment in innovative drug R&D and establishing R&D centers and innovation departments to further enhance their innovation capabilities
.
For example, on December 6, Weiming Medicine issued an announcement stating that it decided to establish a "Global Biosafety and Innovation Institute" as the main department to formulate, supervise and implement the biosafety systems in each subsidiary and each process, and build a biosafety barrier
.
According to the announcement, the purpose of establishing the Global Institute of Biosafety and Innovation is mainly to make the company’s medium and long-term strategic goals serve the national biosafety strategy, consolidate the cornerstone of biosafety, build the company’s biosafety barrier, and promote the development and development of national and global biotechnological innovations.
Play a leading role in the construction of a community with a shared future for human life and health
.
In terms of innovation investment, judging from relevant data, domestic pharmaceutical companies are also increasing
.
It is understood that in the first three quarters of this year, research and development of local pharmaceutical companies was "in full swing.
" Over 80% of A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year
.
From the perspective of total investment, 120 pharmaceutical companies have invested more than 100 million yuan in research and development, exceeding 90 in the same period last year
.
Among them, six companies have invested more than 1 billion yuan in R&D, namely Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Mindray Medical, Junshi Biology, Shanghai Pharmaceuticals, and Kelun Pharmaceuticals.

.
The R&D investment of these six pharmaceutical companies in the first three quarters was 4.
142 billion yuan, 2.
414 billion yuan, 1.
629 billion yuan, 1.
423 billion yuan, 1.
367 billion yuan, and 1.
189 billion yuan, an increase of 23.
86%, 28.
55%, and 20.
64 respectively compared with the same period last year.
%, 17.
56%, 31.
38% and 18.
97%
.
In addition, there are 69 pharmaceutical companies that have invested more than the full year of 2020 in R&D
.
The development of domestic innovative drugs still needs to be strengthened in these aspects.
On the whole, in order to accelerate innovation, domestic pharmaceutical companies are increasing their investment and the forms are becoming more and more diversified
.
However, it is worth noting that the industry believes that in addition to continuing to accelerate the development of domestic innovative drugs in the future; in terms of R&D management, pharmaceutical companies should also play the role of R&D managers to improve R&D capabilities, including basic research and targets.
Screening and clinical trial design and execution
.
Analysts believe that in terms of improving R&D management, if pharmaceutical companies have sufficient R&D capabilities, they can rely on their own strength to conduct R&D and focus on organic growth in the current limited competitive therapeutic field
.
If your own R&D strength is insufficient or there are difficulties, you can also cooperate with outsourcing research institutions to speed up the research and development of innovative products while sharing costs
.
"Using the drug R&D outsourcing service platform to carry out projects can increase capital utilization, put more funds on project products, and reduce investment in fixed assets such as equipment, workshops, etc.

On the other hand, it takes a long time to build R&D centers and R&D teams.
, While R&D outsourcing saves drug R&D time, it also helps the company reduce risks
.
" Some pharmaceutical company personnel said
.
Conclusion In general, driven by multiple forces such as policies and capital, China's innovative drug industry will enter a stage of rapid development
.
In the context of the constant enthusiasm of the innovative drug capital market, listed drug companies are competing to build innovative departments, R&D centers, or introduce new drugs
.
The industry believes that in the future, only companies with continuous R&D capabilities and true innovation capabilities will be recognized by the capital market
.